Projects

International

• European Network for Sigma-1 Receptor as a Therapeutic Opportunity
  Program: COST
  Duration: 25. 10. 2024 – 24. 10. 2028

• Metabolic therapy of heart failure: which role for B vitamins
  Program: ERANET
  Duration: 1. 4. 2020 – 31. 3. 2024

• A4L_ACTIONS Interorganellar communication malfunction in rare diseases – implication for heart contractility
  Program: Other
  Duration: 1. 3. 2023 – 29. 2. 2024

• RyRinHeart - Discovery of Ryanodine Receptor Inhibitors for Heart Diseases
  Program: Bilateral - other
  Duration: 1. 1. 2020 – 31. 12. 2022

National

• Molecular mechanisms implicated in corticosteroid-monoamine interaction in stress-related cardio- and neuropathologies
  Program: SRDA
  Duration: 1. 7. 2023 – 30. 6. 2027

• Therapeutic role of selective ChE inhibition in heart failure
  Program: SRDA
  Duration: 1. 7. 2023 – 30. 6. 2027

• Mitochondrial disease in heart failure
  Program: SRDA
  Duration: 1. 7. 2022 – 30. 6. 2026

• Mutations associated with Wolfram syndrome: alternative signaling pathways for calcium and mitochondrial physiology
  Program: SRDA
  Duration: 1. 7. 2022 – 30. 6. 2026

• Dyad remodelling in cardiomyocytes in experimental therapy of failing heart
  Program: VEGA
  Duration: 1. 1. 2021 – 31. 12. 2024

• Mechanisms of skeletal muscle adaptation to regular exercise in patients with chronic metabolic and inflammatory disease
  Program: VEGA
  Duration: 1. 1. 2019 – 31. 12. 2022

• Regulation of Pericellular Proteolysis: From Molecular Mechanisms To Novel Immune Cell Subsets and Therapeutic Tools
  Program: SRDA
  Duration: 1. 7. 2017 – 31. 12. 2021

• Diastolic function of the ryanodine receptor and generation of arrhythmogenic calcium waves
  Program: VEGA
  Duration: 1. 1. 2017 – 31. 12. 2019

• Cytoarchitecture of calcium signalling of cardiac myocytes in development of myocardial hypertrophy
  Program: SRDA
  Duration: 1. 7. 2016 – 30. 6. 2019